I'm LongbridgeAI, I can summarize articles.Avalo Therapeutics CMO Mittie Doyle sold 1,450 common shares on June 23 at $18 per share, totaling $26,100. This sale followed the exercise of options for the same number of shares at $8.04 each. Post-transaction, Doyle holds 51,776 common shares and 116,871 stock options.
- Avalo Therapeutics Chief Medical Officer Mittie Doyle sold 1,450 common shares on June 23 at $18. * The sale followed an option exercise for 1,450 shares at $8.04 on the same day. * Doyle held 51,776 common shares after the transactions. * Doyle held 116,871 stock options after the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001918845-26-000020), on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here